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ABSTRACT 
 
Purpose/Objective: To identify dosimetry, clinical factors and medication intake impacting 
urinary symptoms after prostate radiotherapy. 
Material and Methods: Data describing clinical factors and bladder dosimetry (reduced with 
principal component (PC) analysis) for 754 patients treated with external beam radiotherapy 
accrued by TROG 03.04 RADAR prostate radiotherapy trial were available for analysis. 
Urinary symptoms (frequency, incontinence, dysuria and haematuria) were prospectively 
assessed using LENT-SOMA to a median of 72 months. The endpoints assessed were 
prevalence (grade≥1) at the end of radiotherapy (representing acute symptoms), at 18-, 36- and 
54-month follow-ups (representing late symptoms) and peak late incidence including only 
grade≥2. Impact of factors were assessed using multivariate logistic regression models with 
correction for over-optimism. 
Results: Baseline symptoms, non-insulin dependent diabetes mellitus, age and PC1 (correlated 
to the mean dose) impact symptoms at >1 timepoints. Associations at a single timepoint were 
found for cerebrovascular condition, ECOG status and non-steroidal anti-inflammatory drug 
intake. Peak incidence analysis shows the impact of baseline, bowel and cerebrovascular 
condition and smoking status. 
Conclusions: The prevalence and incidence analysis provide a complementary view for 
urinary symptom prediction. Sustained impacts across time points were found for several 
factors while some associations were not repeated at different time points suggesting poorer or 
transient impact. 
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INTRODUCTION 
 
Advances in prostate radiotherapy aimed at reducing complications call for accurate 
understanding of the relationship between clinical factors and the resultant complications. 
Urinary symptoms following external beam radiotherapy (EBRT) are gaining more importance 
as they affect more patients than rectal symptoms, especially with dose escalation, despite the 
use of more conformal treatment techniques [1]. There is currently a lack of rigorous evidence 
regarding urinary complications [2]. 
 
Apart from the dosimetric factors [3-6], urinary symptoms have been demonstrated to be 
influenced by other comorbidities, including hypertension [7, 8], diabetes [9, 10] and baseline 
urinary symptoms [11, 12]. There are suggestions that the intake of certain medications related 
has an impact on the interaction between radiation treatment and biological systems, which 
influences the expression of symptoms [10, 13]. Anti-hypertensive medication [5] and anti- 
coagulants [10] were associated with a higher risk of acute and late urinary symptoms, 
respectively. The protective impact of angiotensin converting enzyme (ACE)-inhibitor (ACE) 
intake has been suggested in other organ systems [13]. 
 
Considerable clinical and medication intake data were collected in the TROG-03.04 trial of 
Randomised Androgen Deprivation and Radiotherapy (RADAR-NCT00193856) [14, 15]. In 
this analysis, we sought to identify the dosimetric and clinical factors, including medication 
intake, impacting urinary symptoms after prostate radiotherapy. 
 
 
METHODS AND MATERIALS 
Patients and treatments 
The RADAR trial examined the influence of the duration of androgen suppression (AS) therapy 
with or without bisphosphonate treatment, adjuvant with radiotherapy. Data collection, 
protocol requirements and QA have been summarised previously [15-18]. Accrual was from 
23 centres in Australia and New Zealand between 2003 and 2008. All participants received 
centre-nominated radiotherapy where 813 had EBRT (without a brachytherapy boost) to either 
66, 70 or 74 Gy delivered in up to 2 treatment phases. Of these, 754 had sufficient dosimetric 
and clinical data available for inclusion in the analysis presented here, comprising; 
- Digital treatment plan export consisting of axial computed tomography (CT) slices at 
maximum 5 mm spacing. 
- Form-based information on patient clinical factors comprising physical characteristics, 
comorbidities, medication intake and lifestyle factors captured at randomisation. 
More complete descriptions of the study protocol and treatment technique specifications can 
be found elsewhere [18]. 
 
Principal components of bladder dose-surface histogram 
The digital radiotherapy treatment plan for every patient, incorporating CT images, delineated 
anatomical structures, treatment plan parameters and 3-dimensional dose matrix, was 
independently reviewed using the SWAN [19] and archived. Delineation of the bladder was 
not mandatory for RADAR, thus, all plans were manually reviewed and bladder outlining either 
verified or manually added. No specific dose constraints were applied by RADAR for the 
bladder. Dose-surface histograms (DSH) of the bladder wall were calculated independently 
using SWAN to ensure consistency across datasets submitted from different centres [20]. 
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Physical doses to each voxel in the dose matrix for each treatment phase were combined to 
generate EQD2 – the equivalent dose in 2 Gy fractions - using an α/β of 6 Gy [2, 21]. Dose 
bins of 0.1 Gy were used to calculate the dose received by the bladder wall surface using 
relative surface area of tissue receiving more than a threshold dose. Due to the high correlation 
between dose-area indices (Appendix-A), the use of such data in a multivariate analysis would 
result in multicollinearity problems. Thus, the DSH indices in multiples of 5 Gy were used to 
produce uncorrelated principal components which account for most of the variances in smaller 
dimensions. Applications of this dimensional reduction method has been shown in previous 
dose-response studies [22, 23]. 
 
Symptom prevalence and incidence 
Urinary symptoms (dysuria, incontinence, frequency and haematuria) were assessed using 
LENT-SOMA [24]. Baseline were assessed at randomisation prior to any intervention. The 
patients were then followed up in clinic every 3 months for 18 months, then 6 monthly up to 5 
years post randomisation and then annually. The median follow-up of 72 months is available. 
Schmid et al. demonstrates that the majority of urinary symptoms following EBRT are transient 
[25]. Reporting the incidence rate alone may overestimate the actual symptom burden and may 
have higher level of cumulative noise [25, 26], thus, both prevalence and incidence are reported 
in the current analysis. The symptom prevalence at the end of radiotherapy treatment represents 
the acute symptoms while the prevalence at 18-, 36- and 54-month post randomisation follow- 
ups represent the late symptoms. Grade ≥1 are taken into account and not dichotomised to 
maximise data utilisation. Potential noise associated with low-grade symptoms is kept at a 
minimal level in the prevalence analysis as it is not accumulated across follow-up. Peak 
symptom grade at or beyond the 12-month follow-up (~5 month post-radiotherapy) was utilised 
in the incidence analysis. Grade ≥ 2 at any time as long as the follow-up is available is 
considered as an ‘event’. For the rest of this paper, dysuria after the end of treatment will 
abbreviated as Dysacute while at 18-, 36- and 54-month post randomisation, and the peak event 
as Dys18, Dys36, Dys54 and DysPeak, respectively. Similar convention is used for haematuria 
(Haem), incontinence (Incont) and frequency (Freq). Follow-up data were frozen at November 
2012. 
 
Statistical analysis 
The potential predictors include the reduced dosimetric variables (based on principal 
component analysis) and all clinical factors listed in Table 1. Logistic (for incidence) and 
ordinal logistic (for prevalence) regression methods were used to create logit prediction models 
for the associations between potential predictors and endpoints, first, by univariate analysis. 
Collinearity among the variables was assessed using correlation coefficients. When two or 
more variables are correlated (Spearman correlation coefficient, ρ>.5), only one variable which 
has been previously suggested to be associated to urinary symptoms was included in the 
multivariate variable selection. Clinical variables whose distributions are too narrow (i.e. 
prevalence <5%) were not included. Backward variable selection where the deletion or 
inclusion of variable is based on Bayesian information criterion (BIC) was performed to 
identify the main variables that explain the endpoints. BIC introduces a penalty term for the 
number of parameters in the model and the procedure stops when the model cannot be 
improved without overfitting the model. 
 
Internal validation and calibration were performed using resampling with replacement 
techniques (bootstrapping) that incorporated the variable selection process. The variable 
selection procedure was repeated for all 1000 re-samples and the resultant coefficient estimates 
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of each bootstrap sample were calculated on the original data, and a calibration slope (CS) was 
estimated [27]. CS=1 indicates a perfectly fitted model. CS<1 indicates over-fitting of the 
model reflecting the need for shrinkage to be applied to the coefficients by multiplying the 
estimates to the CS [27]. The performance of the prediction model was assessed using the area 
under the receiver operating characteristic curve (AUC). The AUCs were corrected for 
optimism by an internal validation procedure [28]. 
 
To address the multiple comparisons problem, adjustment for false discovery rate (FDR) was 
performed using the Benjamini–Hochberg procedure [29]. The FDR-adjusted two-sided p- 
value of <0·05 was considered significant. Statistical analysis was performed using ‘R’ (R 
Development Core Team), mainly, the rms package [28]. 
 
 
RESULTS 
Data and Symptom Description 
Distributions of clinical variables including the medication intake status are shown in Table 1. 
Table 2 shows the distribution of patients’ symptom grades at the end of treatment, 18-month, 
36-month and 54-month follow-up and the distribution of peak incidence. The rate of Grade ≥ 
2 symptoms for RADAR participants trial is low as discussed in previous publications [15, 16]. 
The evolution of urinary symptoms for each patient is presented in Appendix-B. 
 
Principal components 
About 89% of the variability of DSH is described by the first two principal components (PCs). 
Because the third PC explained less than 5% of variation, only the first two PCs (PC1 and PC2) 
were retained. The correlation of PC1 and PC2 to dose-surface indices are illustrated in Fig. 1. 
Briefly, PC1 is correlated with relative bladder surface receiving low and intermediate dose 
and has high correlation to the mean dose (ρ=1) while PC2 correlates mostly to the high doses. 
 
Univariate outcome analysis 
Odds ratios for factors studied to affect the symptom by univariate analysis are shown in 
Appendix-C. Baseline were found to be consistently predictive across most endpoints. Several 
clinical factors were found to have sustained impact (≥2 time points) on specific symptoms; 
BMI, non-insulin dependent diabetes mellitus (NIDDM) and smoking status for dysuria, 
hypoglaecemic agent intake for haematuria, cerebrovascular condition and alcohol intake for 
incontinence and hypertension and bladder volume for frequency. For dosimetric factors only 
PC1 was found to be important. 
 
Variable selection and multivariate analysis 
Hypertension, dyslipidaemia, NIDDM and bladder volume were correlated to the ACE intake 
(Spearman's rho, ρ=0.57), statin (ρ=0.78), hypoglycaemic agents (ρ=0.69) and PC1 (ρ=-0.71), 
respectively. Previous studies have suggested the association of hypertension to treatment- 
related symptoms may relate to the medication intake [7] while Wedlake et al. shown the 
reduction of treatment-related symptoms with the intake of statin and ACE [13] - therefore, the 
comorbidities were not included in the multivariate models. NIDDM, however, was included 
due to the impact previously shown [9, 10]. The negative correlation between the bladder 
volume and the dosimetric factor PC1 is expected due to the inclusion of larger relative 
bladder volume in the high dose region in patients with smaller/empty bladder [30]. As post-
treatment symptomology is more logically explained by the bladder dosimetry rather than the 
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bladder size itself, only PC1 is included as a candidate. IDDM, collagen disorder, thyroid 
disorder and steroid intake were excluded not included due to the low prevalence (<5%). 
 
In the prevalence multivariate analysis, the most predictive parameters were found to be the 
baseline symptoms (Table 3). Even so, the strength of baseline symptoms to predict dysuria 
diminishes for longer follow-up; Dys54 and Incont54. Also, the baseline symptoms do not 
significantly affect Haemacute, Haem36, Haem54. NIDDM is the only factor consistently 
affecting dysuria across all time points. NIDDM significantly affects Dys36 (odds ratio 
(OR)=3.30) and Dys54 (OR=6.00), and included in the model for Dysacute (OR=1.51,p=0.107), 
Dys18 (OR=2.21,p=0.079). NIDDM is also selected for Haem18. Increasing age significantly 
associated with decreasing Dysacute (OR= 0.96/year) and Dys54 (OR=0.91/year). Several factors 
were significantly associated with specific endpoints at specific time points; cerebrovascular 
condition increases the risk of Incont18 (OR=4.88) and Freq54 (OR=3.18), ECOG status of 1 is 
associated with a higher risk of Freq36 (OR=2.17), NSAIDs intake increase the risk of Dys54 
(OR=4.25) and PC1 is associated with Freqacute (OR=1.07/unit). PC1 shows a trend toward 
significance for Freq54 (OR=1.08/unit, p=0.053). In the peak symptoms multivariate analysis 
(Table 4), similarly strong impacts of the baseline symptoms were found. In addition, smoking 
status (current vs never, OR=4.74) and bowel condition (OR=3.57) are significantly predictive 
of dysuria while cerebrovascular condition (OR=4.00) impacts the incontinence incidence. 
 
Adjustments for optimism were made to not exaggerate the ability of the model to predict the 
outcome for new, independent observations. The internally validated discriminative ability 
yielded AUCs between 0.467 and 0.794, lower for endpoints without a significant predictor. 
Calibration slopes between 0.548 and 0.780 indicate that in case of replication of this analysis 
the resulting coefficients of the final model are on average smaller by that factor. 
 
 
DISCUSSION 
 
There is increasing evidence that urinary symptoms affect more patients than rectal symptoms 
in patients treated with radiotherapy for prostate carcinoma [1]. Understanding the impact of 
dosimetric and clinical factors on urinary symptoms after radiotherapy is crucial to help the 
decision making process for a more tailored treatment and patient care [2]. Data from RADAR, 
with a sufficiently large patient cohort and with long follow-up, is suitable for derivation of 
such evidence. 
 
We have reported on the impact of dosimetric and clinical factors including medication intake 
on the prevalence and incidence of urinary symptoms following prostate radiotherapy. An 
analysis of symptoms by prevalence, including the effects of trial arm and radiotherapy dose 
prescription group for the RADAR trial, has recently been presented [16]. Combination of 
different symptoms into grades (e.g. RTOG scale as in [3, 9, 11, 12]) has the potential to 
obscure relevant associations if individual symptoms have different pathophysiological origins, 
thus, symptoms were atomised. We indeed found several factors which were influencing a 
specific urinary symptom and not others, facilitating a more symptom-specific 
pathophysiological understanding. 
 
In assessing the effects following radiotherapy, there are some circumstances almost unique to 
urinary symptoms. The prevalence of lower urinary tract symptoms, sometimes 
indistinguishable from those related to treatment, is increasing with advancing age [2, 31]. 
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Furthermore, the amelioration of the pre-treatment urinary symptoms after treatment is 
common and clinically relevant [32, 33]. The treatment-related urinary symptoms also show 
significant levels of reversibility [25, 26]. Given the circumstances surrounding the urinary 
symptoms, the use of cumulative or actuarial incidence alone may misrepresent and 
overestimate the actual burden [25, 26]. Thus, the current study used the prevalence at specific 
time points in addition to the peak incidence. 
 
Baseline symptoms were found to offer the strongest predictive value for incontinence and 
frequency across all time points and peak incidence, consistent with previous reports [11, 12]. 
However, as seen via analysis of urinary symptoms in isolation, the effect of baseline is not 
uniformly strong across all symptom types. Dysuria and haematuria at baseline are less 
important factors to the respective long-term prevalence. The diminishing importance of 
baseline symptoms for certain endpoints is potentially related to the improvement of the 
symptoms after radiotherapy treatment shown here and similarly reported by others [26, 32- 
34]. Related to this, increasing age is associated with lower risk for dysuria which might be 
associated to the shrinkage of benign hypertrophic prostate after radiotherapy treatment which 
is more prevalent in older patients [35]. 
 
Probably the most important advantage of the current study was the availability of 
prospectively collected data on comorbidities, medication intake and lifestyle factors. Only 
diabetes is shown to have persistent effect on a specific symptom (i.e.; dysuria) across all time 
points. Diabetes has already been reported to increase the likelihood of delayed radiation- 
induced urinary morbidity [9, 10]. The impact, however, was not found by some others [7, 8]. 
The effect of diabetes to treatment-related urinary symptoms has been associated with the 
weakened ability to heal tissue damage because of microvascular changes related to the chronic 
pathological processes [9, 36]. This study adds two important points to the knowledge; first, 
with the analysis based on prevalence which reduces the accumulation of transient symptoms, 
we have established that the effect of NIDDM is in fact persistent; second, the effect is strong 
for dysuria and potentially haematuria but not incontinence and frequency suggesting different 
pathological pathways. 
 
Significantly worse peak dysuria were found for current smokers compared to those who never 
smoked. Observations by Peeters et al. [11] of increasing late urinary symptoms in patients 
who smoke was dismissed as a random discovery, however, the current study made a similar 
finding suggesting that the relationship is potentially relevant. The impact of smoking has 
previously been found for rectal toxicity associated with amplified vascular damage, tissue 
hypoxia and fibrosis [37]. 
 
PC1, which was significantly associated with urinary frequency, is correlated to the mean dose 
suggesting the importance of global dose distribution for this endpoint as opposed to maximum 
dose frequently suggested to play a bigger role in causation of urinary symptoms [3, 4]. 
Radiotherapy has been associated with reduction in bladder capacity and decrease in bladder 
volume at first sensation [38]. This study has put forward the potential of the physiological 
changes to be related to the bladder dose-surface information requiring a more detailed 
urodynamic study. Despite that, the relationships between PCs and other urinary symptoms 
were poor. There are several potential explanations; first, the PCs which summarise most of 
the DSH variances into two variables do limit the search space for potential correlations. 
Limiting the search space has the benefit of generating a general understanding of the overall 
impact of DSH features whilst preventing random discovery associated with searching for
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optimal cutpoints in the high dimensional space of the original DSHs. However, correlating 
symptoms to specific dose-surface cutpoints may provide specific and stronger dosimetry- 
symptom relationships. Second, due to generally open bladder filling protocol in the trial 
where centres may decide to use empty or full bladder, there were large variations of bladder 
volume. The relative surface of bladder receiving a particular dose threshold may be 
impacted by the bladder filling due to the expansion of the bladder, known to be anisotropic, 
and this may influence the resultant dosimetric impact [39]. 
 
We identified cerebrovascular condition, worse ECOG status and NSAIDs intake as factors 
increasing the risk of specific urinary symptoms by multivariate analysis at a specific time. 
These factors, however, do not show associations in other time points studied and only 
cerebrovascular condition shows association in the incidence analysis. There are several ways 
to view these observations; 
 
1. The impacts of these clinical factors may be temporally specific. Treatment-related 
radiotherapy injury is complex where the process of healing undergoes a series of 
events that are yet to be fully comprehended [36]. Conventionally, toxicity studies 
separate the events into two phases, acute and late, of which acute symptoms are defined 
as symptoms happening in the first 3 months after the end of treatment while late 
symptoms are defined as all symptoms occurring after that [11, 34]. It has been shown 
that the two phases do not share a similar set of predictors suggesting potentially 
different pathophysiological processes [11, 34]. However, in such analyses the late 
effects definition spans many years until the last follow-up which makes the 
understanding of the symptoms’ evolution challenging. Distinct predictors between late 
symptoms occurring in the first 3 years and those occurring later has been illustrated by 
Fellin et. al. [40] on rectal incontinence and bleeding. Few, if any, have attempted to 
study the important predictors of urinary symptoms across more refined phases. 
2. The reversibility of treatment-related urinary symptoms plays an important role [25, 
26]. The improvements due to the natural healing process or successful management 
may introduce fluctuation of association at different time points. The increased risk of 
dysuria for younger patients, for example, was strong at the end of radiotherapy 
treatment but not repeated until at 54-month follow-up suggesting the fluctuation across 
follow-up time. 
3. The observations may also be fortuitous. As some of the observations are 
counterintuitive (e.g. higher risk for younger patients) or involving clinical factors 
rarely studied (e.g. cerebrovascular condition), there are needs for validation from other 
datasets. 
 
The impact of other comorbidities and medication intake, found to be significant in other 
studies, was not identified in this cohort. Examples include the protective effect of hypertension 
which was suggested to be associated to antihypertensive medication intake [7], and 
exacerbation of haematuria with anticoagulant intake [2, 10]. 
 
Despite several strengths, this study has several limitations. The clinical factors and medication 
intake were only acquired at randomization. It is likely that patients were diagnosed with other 
comorbidities and prescribed with different types of medication at any time after that. It is also 
acknowledged that a DSH derived from a single treatment plan is only a surrogate parameter 
for the actual dose distribution received by the patient [41]. 
 CONCLUSION 
Several parameters impacting specific urinary symptoms after prostate cancer radiotherapy 
were identified. Baseline symptoms and NIDDM were found to have sustained impacts across 
all time points while age and PC1 were repeated in more than one time point. Other associations 
found to be significant are not repeated at different time points suggesting poorer or transient 
impacts. Different impacts of clinical factors from prevalence and incidence analysis providing 
a complementary view for urinary symptoms prediction. 
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Table 1: Distributions of investigated variables. Continuous distributions are specified as mean 
± standard deviation (range), categorical variables are specified as number of patients (%). Not 
all patients available for all assessments due to missing data, exclusions etc. 
 
Factors  Missing 
Physical & Trial factors 
Age 69 ± 7(49-85) years 3 
BMI 27.98 ± 4.12 
(17.17-45.77) kg/m2 
22 
ECOG Performance Status (=1) 123 (16%) 1 
Arm A  (191),  B  (187),  C  (192),  D 
(184) (refer to [15, 16] 
0 
Bladder volume 219.4±89.9 (61.0-561.7) cm3 13 
Comorbidities 
Cardiovascular condition 217 (29) 0 
Peripheral vascular condition 44 (6) 0 
Cerebrovascular condition 37 (5) 0 
Hypertension 353 (49) 1 
Dyslipidaemia 248 (33) 2 
NIDDM 92 (12) 2 
IDDM 14 (2) 0 
Respiratory disorder 99 (13) 0 
Bowel disorder 91 (12) 1 
Dermatological disorder 52 (7) 1 
Collagen disorder 15 (2) 1 
Bone or calcium metabolism 
disorder 
66 (9) 1 
Haematological disorder 11 (1) 1 
Thyroid disorder 24 (3) 1 
Medication intake 
Insulin 14 (2) 6 
Hypoglycaemic agents 55 (7) 7 
ACE Inhibitor 240 (32.1) 8 
Statin 221 (29.6) 8 
Steroids 24 (3) 8 
NSAID 136 (18.2) 6 
Anti-coagulant 120 (16.0) 6 
Antioxidants, flavonoids, phyto- 
oestrogens or selenium 
25 (3) 17 
Lifestyle factors 
14  
 
Smoking status Never 274 (36) ; 
Previous 380 (50) ; 
Current 99 (13) 
1 
Alcohol intake None 100 (13) ; 
Occasional 279 (37) ; 
Regular 370 (49) 
5 
No. of patients with no missing 
information: 711 
Abbreviations; OR- Odds ratio; BMI - body mass index; ECOG - ECOG Performance Status; 
NIDDM – non-insulin dependent diabetes mellitus; IDDM – insulin dependent diabetes 
mellitus; ACE - angiotensin-converting-enzyme; NSAID – non-steroidal anti-inflammatory 
drugs; PC- principal component. 
 
 
 
 
 
 
 
 
Table 2: Number of patients in each grade of symptoms at the end of treatment and at 18-, 36- 
and 54-month follow-ups and the peak late symptom. 
 
Symptom Grade End of RT Month 18 Month 36 Month 54 Peak late 
(Grade≥2, 
dichotomised) 
Dysuria 0 361 655 599 459 693 
 1 252 45 31 20 53 
 2 106 12 5 7  
 3 32 4 0 1  
Haematuria 0 734 702 620 469 729 
 1 15 13 15 11 17 
 2 3 1 2 4  
 3 0 0 0 1  
Incontinence 0 648 665 582 444 657 
 1 59 37 41 29 89 
 2 42 14 15 12  
 3 3 0 1 1  
Frequency 0 128 477 458 349 530 
 1 316 186 154 110 216 
 2 249 51 21 27  
 3 59 2 3 0  
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Table 3: Multivariate analysis examining relationship between the dosimetry, clinical factors and medication intake to the prevalence of urinary 
symptoms (Grade ≥ 1) at the end of treatment, 18-, 36- and 54-month follow-up post randomisation. Discriminative values measured by the 
optimism-corrected area under the receiver operating characteristic curve. The calibration slopes quantify the optimism of coefficients. 
 
Note: Significant factors are bold, *the respective odds ratio can be calculated with the normal convention, ecoefficient and the 95% confidence interval=e(coefficient +/- 1.96*SE), †calibration slope 
describes the optimism of the coefficients, calibration slope<1 suggest overoptimism, to calculate for optimism-adjusted coefficients = coefficient × calibration slope; estimate is based on 1 
grade increase (Baseline), 1 vs 0 (ECOG), per unit (PC1, PC2), per kgm-2 (BMI), year (age), yes vs no (all others); abbreviations - S.E – standard error; P – false-discovery-rate-controlled p- 
value; ACE - angiotensin-converting-enzyme; BMI - body mass index; ECOG - ECOG Performance Status; NSAID – non-steroidal anti-inflammatory drugs; PC- principal component; prev. – 
previous; cond. – condition; AUCa- Apparent area under the receiver operating characteristic curve (AUC); AUCo- Optimism-adjusted AUC. 
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 End of treatment        18 months           36 months        54 months        
Endpoint Variable Coef.*  S.E   P Variable  Coef.  S.E   P Variable Coef. S.E  P Variable Coef. S.E  P 
Dysuria Baseline 0.999  0.179  0.002 Baseline  0.739  0.244  0.014 NIDDM   0.034 NSAIDs 1.447 0.465 0.014 
 Age -0.042  0.011  0.002 BMI  0.069  0.031  0.073 Baseline   0.042 NIDDM 1.791 0.592 0.015 
 Bowel cond. 0.425  0.219  0.104 NIDDM  0.793  0.354  0.079 Smoking status    Age -0.097 0.037 0.042 
 NIDDM 0.413  0.222  0.107 Cerebrovascular  0.924  0.485  0.104 prev. vs never  0.400 0.439 0.382 Cerebrovascular 1.533 0.664 0.073 
 PC2 0.115  0.062  0.108        current vs never  1.171 0.555 0.084 Baseline 0.796 0.365 0.081 
 ECOG 0.289  0.194  0.167        Cerebrovascular 1.064 0.694 0.159 ACE inhibitor 0.939 0.468 0.104 
                      B vs A -0.083 0.519 0.873 Respiratory cond. 0.964 0.540 0.142 
C vs A 0.369 0.462 0.430 Anticoagulant 0.898 0.591 0.167 
D vs A -1.688 0.807 0.086     
 AUCa=0.631   †Calibration slope=0.747  AUCa=0.643    Calibration slope=0.625  AUCa= 0.767  Calibration slope = 0.567  AUCa=0.822   Calibration slope=0.599  
 AUCo=0.594   AUCo=0.556    AUCo= 0.663   AUCo=0.727   
Haematuria Age (/year)  -0.053  0.035  0.176 NIDDM  1.630  0.648  0.073 PC2 -0.638 0.419 0.161 Bowel cond. 1.129 0.624 0.150 
       Baseline  2.487  0.964  0.104 PC1 -0.134 0.091 0.165     
       PC1  0.192  0.090  0.114         
 AUCa=0.608   Calibration slope=0.427  AUCa=0.873    Calibration slope=0.677  AUCa=0.669   Calibration slope =0.458  AUCa=0.576   Calibration slope=0.488  
 AUCo=0.467   AUCo=0.794    AUCo=0.532   AUCo=0.471   
Incontinence Baseline 1.267  0.329  0.002 Baseline  1.069  0.390  0.010 Baseline 1.203 0.336 0.003 Baseline 1.075 0.430 0.050 
 Age (/year) 0.043  0.018  0.053 Cerebrovascular  1.586  0.493  0.036     ACE inhibitor 0.690 0.359 0.104 
 BMI (/kgm
-2) 0.041  0.026  0.148 BMI  0.079  0.035  0.061     Cardiovascular -0.910 0.484 0.104 
 Arm      ECOG  0.716  0.371  0.104     Respiratory cond. 0.630 0.420 0.165 
 B vs A -0.278  0.319  0.400 PC2  -0.334  0.183  0.129         
 C vs A -0.527  0.329  0.148 Cardiovascular  -0.684  0.393  0.148         
  D vs A 0.240 0.288 0.418   
 AUCa= 0.665  Calibration slope = 0.636  AUCa=0.697    Calibration slope=0.640  AUCa=0.568   Calibration slope=0.596  AUCa=0.651   Calibration slope=0.548  
 AUCo= 0.591   AUCo=0.609    AUCo=0.475   AUCo=0.555   
Frequency Baseline 0.645  0.114 <0.001 Baseline   0.815  0.130 <0.001 Baseline 0.773 0.145 <0.001 Baseline 0.893 0.163 <0.001 
 PC1 0.068  0.021 0.008 Arm       ECOG 0.731 0.238 0.012 Cerebrovascular 1.158 0.444 0.040 
 NSAIDs 0.376  0.184 0.094  B vs A  -0.242  0.258 0.370 Smoking status    PC1 0.075 0.032 0.064 
 ACE inhibitor -0.247  0.151 0.148  C vs A  0.522  0.238 0.075 current vs never  0.416 0.316 0.208 Anticoagulant -0.694 0.343 0.098 
 PC2 0.093  0.058 0.148  D vs A  0.670  0.235 0.020 prev. vs never  0.426 0.210 0.095 Bone/calcium 0.624 0.355 0.129 
                 metabolism disorder    
 ECOG 0.289  0.191 0.161 BMI   0.035  0.020 0.129 NSAIDs 0.376 0.238 0.137     
 AUCa=0.633   Calibration slope =0.780  AUCa= 0.663   Calibration slope = 0.755  AUCa=0.678   Calibration slope=0.765   AUCa=0.682   Calibration slope=0.743  
 AUCo=0.602   AUCo= 0.620    AUCo=0.633    AUCo=0.630   
 
 
 
 
 
 
 
 
 
 
BMI -0.025 0.018 0.171 Arm Statin -1.109 0.556 0.104 
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Table 4: Multivariate analysis examining relationship between the dosimetry, clinical factors 
and medication intake to the incidence of late urinary symptoms (Grade ≥ 2). 
 
Peak incidence Grade >1  
Endpoint Variable Coef. S.E  P 
Dysuria Smoking status    
 prev. vs never 0.330 0.384 0.430 
 current vs never 1.562 0.456 0.008 
 Bowel cond. 1.272 0.374 0.011 
 Baseline 0.841 0.285 0.048 
 BMI 0.069 0.036 0.104 
 Statin 0.504 0.327 0.164 
 Peripheral 
   vascular condition   
-1.578 1.068 0.167 
 AUCa=0.738  
  AUCo=0.656    
Calibration slope= 0.662  
Haematuria Bowel cond. 1.122 0.577 0.104 
 Statin 0.886 0.525 0.129 
    BMI   0.088   0.056   0.148   
 AUCa=0.718  
  AUCo=0.592    
Calibration slope= 0.537  
Incontinence Baseline 1.341 0.367 0.003 
 Cerebrovascular 1.385 0.434 0.010 
    Anticoagulant   -0.611   0.381   0.148   
 AUCa=0.608  
  AUCo=0.532    
Calibration slope = 0.651  
Frequency Baseline 0.835 0.136 <0.001 
 Age 0.033 0.014 0.053 
 ECOG 0.491 0.229 0.081 
 PC1 0.049 0.026 0.104 
Arm 
 B vs A -0.317 0.267 0.254 
 C vs A 0.442 0.245 0.116 
   D vs A   0.314   0.251   0.230   
 AUCa= 0.693  
  AUCo= 0.647    
Calibration slope = 0.760  
 
 
Note: Refer Table 3 for abbreviations and notes. 
18  
 
 
 
Fig. 1: Correlation, ρ of the first and second principal components (PC1 and PC2) to EQD2. 
Percent variance described by eigenvector is shown in parentheses. 
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Appendix-A: Correlation of dose-surface indices 
 
 
 
Appendix-B: Profile of patient-wise i) dysuria (ii) haematuria, (iii) incontinence and (iv) 
frequency after prostate cancer radiotherapy for 754 patients (distributed vertically) ordered by 
baseline symptoms at the end of radiotherapy (End), each follow-up visit (9-84-month follow- 
up) and the peak late grade (dys.max, haem.max, incont.max, freq.max). The colours indicate 
the grade. The colours indicate the grade of symptoms, white: no data. 
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Appendix-C: Univariate analysis of all clinical factors studied. 
 
Factor Dysacute Dys18 Dys36 Dys54 Haemacute Haem18 Haem36 Haem54 Incontacute Incont18 Incont36 Incont54 Freqacute Freq18 Freq36 Freq54 
Physical factors        Odds ratio        
Age (per year) 0.97 0.99 0.98 0.96 0.95 0.95 0.97 0.99 1.04 1.01 1.02 1.01 1.00 1.01 1.01 1.02 
BMI (per 1kgm-2) 0.99 1.09 1.03 1.11 1.04 1.08 1.06 1.07 1.04 1.08 1.05 1.06 0.98 1.02 1.00 1.01 
ECOG (1 vs 0) 1.22 1.72 1.76 0.86 1.02 0.38 1.57 0.34 1.34 1.60 1.06 0.85 1.39 1.40 2.42 1.30 
Bladder volume (per 10 cm3) 1.00 0.99 1.01 1.00 1.02 0.95 1.02 1.03 0.99 0.98 0.99 0.99 0.98 0.98 0.97 0.97 
Comorbidities 
Baseline 2.68 2.09 2.09 1.93 - 11.43 - - 3.45 3.19 3.76 3.03 1.93 2.12 2.27 2.42 
Cardiovascular condition 1.04 1.16 0.96 1.34 1.23 0.41 1.37 0.94 0.99 0.76 0.78 0.53 0.89 0.85 0.96 0.97 
Peripheral vascular condition 0.74 0.82 0.46 1.30 2.10  1.04 1.17 1.35 0.66 0.58 0.82 0.77 0.77 1.37 0.99 
Cerebrovascular condition 0.87 2.39 2.23 4.41 1.13 1.46 1.37 1.27 2.23 3.74 1.69 2.30 1.42 1.80 1.88 3.08 
Hypertension 0.93 1.31 1.06 2.33 0.72 1.10 2.22 0.56 1.09 1.39 0.99 1.15 1.00 1.38 1.28 1.53 
Dyslipidaemia 1.06 1.24 1.35 1.14 1.64 2.01 1.33 0.94 1.53 1.26 1.60 1.42 1.23 1.24 1.21 1.27 
Diabetes - IDDM 0.28 0.97 1.66 - - - - - 1.16 - 1.01 - 0.72 0.18 0.25 3.04 
Diabetes - NIDDM 1.37 2.20 2.68 2.65 1.46 4.30 1.62 0.58 1.36 1.62 1.21 1.48 0.81 1.19 1.18 0.97 
Respiratory disorder 0.83 1.42 0.55 1.66 0.83 0.49 0.84 1.36 1.46 1.22 0.87 2.07 0.98 0.78 0.63 1.30 
Bowel disorder 1.36 1.39 1.85 0.87 0.90 1.24 0.98 2.59 1.28 1.21 1.63 1.00 1.29 0.92 1.20 1.14 
Dermatological disorder 0.93 1.17 0.74 0.98 - - - 0.84 0.66 0.81 0.44 1.82 1.34 1.18 0.99 1.12 
Collagen disorder 1.04 2.80 3.35 5.22 - - - 4.19 1.65 - - 1.68 1.20 1.09 0.82 0.94 
Bone or calcium metabolism 
disorder 
1.29 0.92 1.08 1.33 0.60 1.71 - - 0.59 1.13 1.41 1.89 1.43 1.15 1.34 1.84 
Haematological disorder 0.69 - - - - - - - 1.26 1.41 - 2.36 1.16 0.53 1.20 1.74 
Thyroid disorder 0.95 2.66 1.86 2.70 1.80 - 1.86 4.42 0.56 1.28 - - 1.21 1.12 0.58 1.37 
Medication intake 
Insulin 0.26 0.87 1.50 - - - - - 1.64 - 0.90 - 0.71 0.34 0.49 2.06 
Hypoglycaemic agents 1.47 2.16 2.25 0.58 2.62 3.74 2.90 1.03 1.87 1.10 2.25 1.65 0.92 1.10 1.43 1.10 
ACE Inhibitor 0.98 1.59 2.05 1.99 0.60 0.85 1.99 0.76 1.10 1.87 1.31 1.61 0.77 1.09 0.80 1.40 
Statin 1.12 1.01 0.97 0.90 0.91 1.77 2.02 1.04 1.36 1.20 1.30 1.42 1.00 1.15 1.08 1.06 
Steroids 0.70 0.49 1.66 3.29 1.78 - 0.78 1.62 1.81 1.40 1.73 2.17 1.25 0.58 0.76 1.44 
NSAID 1.17 1.06 1.33 2.97 0.89 0.33 1.42 1.42 0.97 1.20 1.07 1.00 1.23 1.22 1.26 1.32 
Anti-coagulant 1.13 1.44 1.29 1.61 0.65 0.84 1.60 1.35 1.15 1.09 0.82 0.77 1.16 1.14 0.86 0.69 
Antioxidants, flavanoids, phyto- 
oestrogens or selenium 
1.13 - 0.73 5.05 1.69 - 1.66 1.70 0.53 - 1.02 - 0.98 1.04 1.18 2.08 
Lifestyle factors 
Smoking status, (previous vs never) 1.11 1.97 1.73 0.82 0.89 2.34 0.77 - 1.08 1.49 1.36 0.98 1.13 1.15 1.49 0.93 
(current vs never) 1.61 1.95 2.79 0.52 2.65 2.14 1.45 - 1.36 1.72 1.55 0.99 1.13 1.25 1.75 0.98 
Alcohol intake (occasional vs no) 0.98 1.03 1.38 0.95 0.43 2.11 0.42 2.95 0.49 0.39 0.71 0.60 1.17 1.26 1.03 0.70 
(regular vs no) 1.07 1.63 1.86 1.49 0.59 1.80 0.51 1.81 0.60 0.70 0.81 0.60 1.02 1.05 1.15 0.82 
Dosimetric factors 
PC1 (per unit) 1.01 1.02 1.07 1.02 0.99 1.26 0.92 0.92 1.02 1.05 1.04 1.01 1.07 1.03 1.03 1.05 
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PC2 (per unit) 1.10 1.05 1.06 1.04 0.85 1.21 0.65 1.00 1.00 0.78 0.84 0.98 1.10 0.97 0.96 0.90 
26  
 
Dyspeak Haempeak Incontpeak Freqpeak 
Physical factors 
Age (per year) 0.98 0.99 1.03 1.03 
BMI (per 1kgm-2) 1.06 1.11 1.02 1.01 
ECOG (1 vs 0) 1.55 2.34 1.16 1.91 
Bladder volume (per 10 cm3) 0.99 1.03 1.01 0.97 
Comorbidities 
Baseline 1.86 - 4.11 2.28 
Cardiovascular condition 1.08 0.86 0.90 0.85 
Peripheral vascular condition 0.30 2.17 0.75 0.96 
Cerebrovascular condition 1.77 2.74 3.77 1.49 
Hypertension 1.25 1.92 1.26 0.95 
Dyslipidaemia 1.86 2.14 0.87 1.13 
Diabetes - IDDM - - 0.67 0.22 
Diabetes - NIDDM 1.31 0.49 1.07 0.80 
Respiratory disorder 1.18 0.45 1.36 1.06 
Bowel disorder 3.14 3.58 1.36 1.07 
Dermatological disorder 0.60 2.07 1.40 1.13 
Collagen disorder 1.01 3.34 0.56 1.38 
Bone or calcium metabolism 
disorder 
 
1.30 
 
1.58 
 
1.23 
 
1.16 
Haematological disorder - 4.37 0.74 0.55 
  Thyroid disorder   3.97 4.38 - 0.51 
Medication intake 
Insulin - - 1.49 0.22 
Hypoglycaemic agents 1.68 0.92 1.12 0.58 
ACE Inhibitor 1.44 1.69 1.38 0.83 
Statin 1.51 2.50 1.10 0.97 
Steroids 0.65 - 2.40 0.77 
NSAID 1.34 1.02 1.20 1.36 
Anti-coagulant 1.04 1.20 0.80 0.97 
Antioxidants, flavanoids, phyto- 
  oestrogens or selenium   
 
1.27 
 
- 
 
0.70 
 
0.68 
Lifestyle factors 
Smoking status, (previous vs never) 1.61 0.91 1.06 1.12 
(current vs never) 3.36 1.54 1.42 1.02 
Alcohol intake (occasional vs no) 2.46 2.64 0.52 0.60 
  (regular vs no)   2.45 2.19 0.55 0.75 
B vs A 2.19 1.38 0.88 0.84 
C vs A 1.35 0.74 0.79 1.46 
  D vs A   1.18 1.06 1.12 1.47 
Dosimetric factors 
PC1 (per unit) 1.02 1.01 0.96 1.06 
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  PC2 (per unit) 0.94 0.72 1.05 1.07   
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† Unless stated in parentheses, the odds ratios are the odds for patients with comorbidities/taking medication to patients who did not; - 
analysis did not reach convergence; the p-values were not adjusted for multiple comparisons as this analysis attempted to give an 
overview of the effect of the potential predictors; p<0.05 are bold. Abbreviations; BMI - body mass index; ECOG - ECOG Performance 
Status; NIDDM – non-insulin dependent diabetes mellitus; IDDM – insulin dependent diabetes mellitus; ACE - angiotensin-converting- 
enzyme; NSAID – non-steroidal anti-inflammatory drugs;  PC- principal component 
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